RxDoctor Payments Data

Elica Inagaki

Vascular Surgery · Bellevue, WANPI 1689930380

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (38.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 51.0% of the total. Reporting peaked in 2020 at $4,068 and has fallen 53.3% since, to $1,899 in 2025.

$9,637in general payments, 2019–2025

Across 56 payments — averaging $172.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Globus Medical$1K
  • W. L. Gore & Associates, Inc.$1K
  • Abbott$766
  • Cook Medical LLC$341
  • Endologix LLC$300
  • plus $754 from 8 others

What the payments were for

  • Grants$3,75039%
  • Travel & lodging$2,95531%
  • Food & beverage$2,42225%
  • Education$5095%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,637 in reported general payments places this provider in the 70th percentile of 111 vascular surgery providers in Washington.

See all vascular surgery providers in Washington

Medicare billing

Part B allowed, 2024
$234,571
Medicare patients
570
Services billed
2,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban124$159,491
EliquisApixaban133$142,980
Rosuvastatin Calcium49$1,488
Atorvastatin Calcium75$837
Cilostazol20$564
ClopidogrelClopidogrel Bisulfate14$218
Fludrocortisone Acetate12$113
Oxycodone Hcl21$88
Gabapentin20$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$142,980133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 vascular surgery providers in Washington.

Other vascular surgery in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →